Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
cytoskeletal diseases
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "cytoskeletal diseases" in MCE Product Catalog:
1
1 Cited Publications
(+)-Blebbistatin is the inactive enantiomer of (-)-Blebbistatin (HY-13441). (-)-Blebbistatin is a selective inhibitor of non-muscle myosin II ATPase activity .
Cat. No.: HY-138053
CAS No.: 92989-99-6
Synonyms: Ristomycin III
Target:
Research Areas:
Ristocetin A (sulfate) (Ristomycin III) is a glycopeptide antibiotic that binds to von Willebrand factor (VWF) and bacterial cell wall components. Ristocetin A (sulfate) interferes with the biosynthesis of bacterial peptidoglycan by inhibiting transpeptidation. As an inducer of platelet adhesion and aggregation, Ristocetin A (sulfate) drives conformational changes by binding to the A1 domain of VWF, thereby activating downstream signaling pathways and promoting cytoskeletal rearrangement. Ristocetin A (sulfate) not only enhances platelet adhesion and spreading on immobilized VWF, but also induces the formation of asymmetric dimers with anticooperativity between platelets and plasma VWF. Ristocetin A (sulfate) is widely used in studies related to thromboembolic diseases and bacterial infections .
Target:
Research Areas:
GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC50s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .
Cat. No.: HY-N9941
CAS No.: 30377-37-8
Cat. No.: HY-D2871
CAS No.: 1866495-46-6
Cat. No.: HY-P11319
CAS No.: 1337998-99-8
Target:
Research Areas:
Cat. No.: HY-L060
2,313 compounds
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.
MCE designs a unique collection of 2,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.
Cat. No.: HY-W718178
CAS No.: 152-84-1
Target:
Cat. No.: HY-107657R
CAS No.: 1177356-70-5
Target:
Research Areas:
(+)-Blebbistatin (Standard) is the analytical standard of (+)-Blebbistatin (HY-107657). This product is intended for research and analytical applications. (+)-Blebbistatin is the inactive enantiomer of (-)-Blebbistatin (HY-13441). (-)-Blebbistatin is a selective inhibitor of non-muscle myosin II ATPase activity .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
